177 related articles for article (PubMed ID: 33199495)
1.
Lotan TL; Antonarakis ES
Clin Cancer Res; 2021 Jan; 27(2):380-382. PubMed ID: 33199495
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
[TBL] [Abstract][Full Text] [Related]
4. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
[TBL] [Abstract][Full Text] [Related]
5. Characterizing CDK12-Mutated Prostate Cancers.
Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS
Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
8. Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
Iwasawa T; Kosaka T; Yasumizu Y; Hongo H; Yanai Y; Baba Y; Matsumoto K; Nakamura K; Nishihara H; Oya M
Int J Clin Oncol; 2022 Dec; 27(12):1867-1873. PubMed ID: 36271301
[TBL] [Abstract][Full Text] [Related]
9. The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.
Melo CM; Vidotto T; Chaves LP; Lautert-Dutra W; Reis RBD; Squire JA
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502458
[TBL] [Abstract][Full Text] [Related]
10. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
11. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Popova T; Manié E; Boeva V; Battistella A; Goundiam O; Smith NK; Mueller CR; Raynal V; Mariani O; Sastre-Garau X; Stern MH
Cancer Res; 2016 Apr; 76(7):1882-91. PubMed ID: 26787835
[TBL] [Abstract][Full Text] [Related]
12. Analysis of CDK12 alterations in a pan-cancer database.
Pan E; Cabal A; Javier-DesLoges J; Patel D; Panian J; Lee S; Shaya J; Nonato T; Xu X; Stewart T; Rose B; Shabaik A; Cohen E; Kurzrock R; Tamayo P; McKay RR
Cancer Med; 2022 Feb; 11(3):753-763. PubMed ID: 34898046
[TBL] [Abstract][Full Text] [Related]
13. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
14. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
[TBL] [Abstract][Full Text] [Related]
15. CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
Yang B; Chen J; Teng Y
J Immunol Res; 2021; 2021():6645885. PubMed ID: 33628849
[TBL] [Abstract][Full Text] [Related]
16. A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
Qian K; Wang G; Ju L; Liu J; Luo Y; Wang Y; Peng T; Chen F; Zhang Y; Xiao Y; Wang X
Oncogene; 2020 Oct; 39(44):6871-6878. PubMed ID: 32978518
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.
Zhang W; Zhou L; Di J
Expert Rev Anticancer Ther; 2023 Feb; 23(2):207-216. PubMed ID: 36734254
[TBL] [Abstract][Full Text] [Related]
18. CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
[TBL] [Abstract][Full Text] [Related]
19. The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jenzer M; Keß P; Nientiedt C; Endris V; Kippenberger M; Leichsenring J; Stögbauer F; Haimes J; Mishkin S; Kudlow B; Kaczorowski A; Zschäbitz S; Volckmar AL; Sültmann H; Jäger D; Duensing A; Schirmacher P; Hohenfellner M; Grüllich C; Stenzinger A; Duensing S
Cancer Immunol Immunother; 2019 Oct; 68(10):1621-1633. PubMed ID: 31549213
[TBL] [Abstract][Full Text] [Related]
20. CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Yanai Y; Kosaka T; Nakamura K; Aimono E; Matsumoto K; Morita S; Mikami S; Nishihara H; Oya M
Cancer Sci; 2020 Dec; 111(12):4652-4655. PubMed ID: 33038052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
